GPCR Stock Overview
A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Structure Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.82 |
| 52 Week High | US$62.74 |
| 52 Week Low | US$13.22 |
| Beta | -1.79 |
| 1 Month Change | 89.54% |
| 3 Month Change | -2.12% |
| 1 Year Change | -30.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.15% |
Recent News & Updates
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Mar 20We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate
Mar 11
Structure Therapeutics: Competitive Data Is Emerging
Jan 03Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Nov 25Recent updates
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Mar 20We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate
Mar 11Structure Therapeutics: Competitive Data Is Emerging
Jan 03Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Nov 25Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Oct 22We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely
Aug 11Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Jun 14Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape
Jun 05Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation
Mar 10Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans
Jun 29Shareholder Returns
| GPCR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.9% | -3.1% | 1.3% |
| 1Y | -30.6% | -8.8% | 8.2% |
Return vs Industry: GPCR underperformed the US Pharmaceuticals industry which returned -7.3% over the past year.
Return vs Market: GPCR underperformed the US Market which returned 7.7% over the past year.
Price Volatility
| GPCR volatility | |
|---|---|
| GPCR Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: GPCR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GPCR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 163 | Raymond Stevens | structuretx.com |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis.
Structure Therapeutics Inc. Fundamentals Summary
| GPCR fundamental statistics | |
|---|---|
| Market cap | US$1.53b |
| Earnings (TTM) | -US$122.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-12.6x
P/E RatioIs GPCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GPCR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$122.53m |
| Earnings | -US$122.53m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GPCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 00:32 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Structure Therapeutics Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Zhuhong Chen | China Merchants Securities (HK) Co., Ltd |